S
Synosia Therapeutics
Therapeutics developer for central nervous system disorders
About Synosia Therapeutics
Synosia Therapeutics was a Swiss-based drug development company founded in 2005, specializing in treatments for central nervous system (CNS) disorders. The company was co-founded by Dr. Ian Massey, a veteran drug development executive with extensive experience at Roche and Syntex, who also served as President and CEO. Massey's background in neuroscience drug development was central to Synosia's strategy, which focused on acquiring or in-licensing clinical-stage assets to accelerate their path to market.
The company's business model was centered on forming strategic partnerships with major pharmaceutical firms to develop compounds that had been deprioritized. In 2007, Synosia entered into a significant agreement with Roche to develop a portfolio of five drug candidates for conditions like schizophrenia, cognitive disorders, and Parkinson's disease. This was followed by agreements with Novartis and Syngenta, expanding its pipeline to six clinical-stage compounds. A key candidate was SYN-115, an adenosine A2a antagonist for Parkinson's disease, acquired from Roche.
Synosia successfully raised significant capital to fund its clinical programs, including a $32.5 million initial funding, a $29 million Series B in 2009, and a $30 million Series C round in 2010. The Series C was led by UCB Pharma, which also entered into a strategic alliance potentially worth up to $725 million for two of Synosia's Parkinson's drugs, SYN-115 and SYN-118. In February 2011, Synosia Therapeutics was acquired by the Finnish drug development company Biotie Therapies in a deal valued at approximately €93.6 million (around $122M). Following the acquisition, Dr. Massey took on the role of COO and President of US Operations at Biotie.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Open positions
- None listed
- Dealroom signal
- 15.7/100
- Client focus
- B2C
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Synosia Therapeutics is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Synosia Therapeutics in the Basel ecosystem
The Synosia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Aravis Ventures
Investor Growth Capital
Swiss Helvetia Fund
Novo Ventures
Series B and later4 investors entered at this stage
5AM Ventures
Novo Holdings
Versant Ventures
UCB
Other known investors1 additional known investor
Biotie Therapies
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Synosia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synosia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






